PE20010385A1 - UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO - Google Patents
UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENOInfo
- Publication number
- PE20010385A1 PE20010385A1 PE2000000757A PE0007572000A PE20010385A1 PE 20010385 A1 PE20010385 A1 PE 20010385A1 PE 2000000757 A PE2000000757 A PE 2000000757A PE 0007572000 A PE0007572000 A PE 0007572000A PE 20010385 A1 PE20010385 A1 PE 20010385A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidin
- thiophene
- benzo
- phenoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE AL CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO (ARZOXIFENO), QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS ESTROGENOS, PROGESTAGENOS TAL COMO NORETILNODREL, NORETINDRONA; INHIBIDOR DE AROMATASA, UN ANALOGO DE LHRH, UN INHIBIDOR DE LA ACETIL COLINESTERASA TAL COMO SALICILATO DE FISOSTIGMINA, CLORHIDRATO DE TACRINA, CLORHIDRATO DE DONEPEZILO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE CRISTALIZAR CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b)]TIOFENO EN TETRAHIDROFURANO. EL COMPUESTO ES UN AGONISTA/ANTAGONISTA MIXTO DE ESTROGENOS Y PUEDE SER UTIL PARA REDUCIR LOS NIVELES DE COLESTEROL, INHIBIR LA HIPERLIPIDEMIA, OSTEOPOROSIS, CANCER DE MAMA, CANCER UTERINO, ENDOMETRIOSIS, TRASTORNOS DEL SNC
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14628699P | 1999-07-29 | 1999-07-29 | |
US14757099P | 1999-08-06 | 1999-08-06 | |
US14977399P | 1999-08-19 | 1999-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010385A1 true PE20010385A1 (es) | 2001-04-06 |
Family
ID=27386379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000757A PE20010385A1 (es) | 1999-07-29 | 2000-07-31 | UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO |
Country Status (45)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2208384T3 (es) * | 1999-07-29 | 2004-06-16 | Eli Lilly And Company | Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno. |
EP1757291A3 (en) * | 2000-05-08 | 2009-07-15 | Eli Lilly & Company | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
US7122203B2 (en) | 2000-05-08 | 2006-10-17 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
DZ3376A1 (fr) * | 2000-05-08 | 2001-11-15 | Lilly Co Eli | Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes |
EP1157996A1 (de) * | 2000-05-23 | 2001-11-28 | JENAPHARM GmbH | Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on |
BR0114792A (pt) * | 2000-10-20 | 2003-08-12 | Lilly Co Eli | Composto cristalino, anidro, não solvatado, de cloridreto de 6-hidróxi-3-(-4-[2-piperidin-1-il)-etóxi]-fenóxi)-2-(4-metóx i-fenil)-benzol[b]tiofeno (f-v), formulação farmacêutica, processo para preparar um composto, e uso de um composto |
US6921827B2 (en) | 2000-11-27 | 2005-07-26 | Eli Lilly And Company | Process for preparing 3-aryl-benzo{b} thiophenes |
CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
ES2349798T3 (es) * | 2004-07-22 | 2011-01-11 | Eli Lilly And Company | Hidrato variable cristalino de la sal hemisuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2-hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinocarboxamida. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE44597A1 (es) * | 1995-02-28 | 1997-10-13 | Lilly Co Eli | Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos |
US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
ZA9710262B (en) * | 1996-11-19 | 1999-05-13 | Lilly Co Eli | Process for the synthesis of benzothiophenes |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
-
2000
- 2000-07-17 EP EP00950223A patent/EP1204656A2/en not_active Ceased
- 2000-07-17 AU AU63356/00A patent/AU6335600A/en not_active Abandoned
- 2000-07-17 WO PCT/US2000/016333 patent/WO2001009116A2/en not_active Application Discontinuation
- 2000-07-18 LV LVP-00-94A patent/LV12623B/en unknown
- 2000-07-21 RO ROA200000736A patent/RO121851B1/ro unknown
- 2000-07-24 CZ CZ20002716A patent/CZ299311B6/cs not_active IP Right Cessation
- 2000-07-24 ID IDP20000629D patent/ID27078A/id unknown
- 2000-07-25 HR HR20000503A patent/HRP20000503B1/xx not_active IP Right Cessation
- 2000-07-27 IL IL13755300A patent/IL137553A/xx not_active IP Right Cessation
- 2000-07-27 TR TR2000/02206A patent/TR200002206A2/xx unknown
- 2000-07-27 CO CO00056521A patent/CO5180570A1/es active IP Right Grant
- 2000-07-27 NL NL1015821A patent/NL1015821C2/nl not_active IP Right Cessation
- 2000-07-28 DE DE10036854A patent/DE10036854A1/de not_active Withdrawn
- 2000-07-28 GB GB0018641A patent/GB2352717A/en not_active Withdrawn
- 2000-07-28 TW TW089115154A patent/TWI276437B/zh not_active IP Right Cessation
- 2000-07-28 BR BR0003209-3A patent/BR0003209A/pt not_active Application Discontinuation
- 2000-07-28 SE SE0002792A patent/SE0002792L/xx unknown
- 2000-07-28 IT IT2000MI001759A patent/IT1318660B1/it active
- 2000-07-28 FI FI20001722A patent/FI20001722A/fi unknown
- 2000-07-28 PT PT102502A patent/PT102502A/pt not_active IP Right Cessation
- 2000-07-28 NO NO20003879A patent/NO20003879L/no not_active Application Discontinuation
- 2000-07-28 MY MYPI20003453A patent/MY128764A/en unknown
- 2000-07-28 CA CA002314682A patent/CA2314682A1/en not_active Abandoned
- 2000-07-28 BE BE2000/0478A patent/BE1013411A3/fr not_active IP Right Cessation
- 2000-07-28 SV SV2000000132A patent/SV2002000132A/es unknown
- 2000-07-28 AT AT0132400A patent/AT502318A1/de not_active Application Discontinuation
- 2000-07-28 DK DK200001151A patent/DK200001151A/da not_active Application Discontinuation
- 2000-07-28 CN CNB001222376A patent/CN1138770C/zh not_active Expired - Fee Related
- 2000-07-28 KR KR1020000043651A patent/KR100697177B1/ko not_active IP Right Cessation
- 2000-07-28 MX MXPA00007461A patent/MXPA00007461A/es active IP Right Grant
- 2000-07-28 GR GR20000100265A patent/GR1004084B/el unknown
- 2000-07-28 SI SI200000172A patent/SI20426A/sl not_active IP Right Cessation
- 2000-07-28 SG SG200004288A patent/SG91296A1/en unknown
- 2000-07-28 JP JP2000228939A patent/JP2001064277A/ja active Pending
- 2000-07-28 FR FR0009969A patent/FR2796944B1/fr not_active Expired - Fee Related
- 2000-07-28 LT LT2000076A patent/LT4790B/lt not_active IP Right Cessation
- 2000-07-28 LU LU90617A patent/LU90617B1/fr active
- 2000-07-28 UA UA2000074563A patent/UA72885C2/uk unknown
- 2000-07-28 AR ARP000103928A patent/AR031073A1/es unknown
- 2000-07-28 MD MDA20000162A patent/MD2336G2/ro not_active IP Right Cessation
- 2000-07-28 HU HU0003001A patent/HUP0003001A2/hu unknown
- 2000-07-28 PL PL00341749A patent/PL341749A1/xx not_active Application Discontinuation
- 2000-07-29 DZ DZ000126A patent/DZ3060A1/xx active
- 2000-07-31 PE PE2000000757A patent/PE20010385A1/es not_active Application Discontinuation
-
2001
- 2001-09-03 HK HK01106204A patent/HK1035370A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010385A1 (es) | UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO | |
PE20060853A1 (es) | 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen | |
PE20010383A1 (es) | NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO | |
SK282188B6 (sk) | Purifikovaná zlúčenina | |
AR022254A1 (es) | Composicion de administracion oral. | |
FI925652A (fi) | Foerfarande och sammansaettningar foer foerhindrande av befruktning och behandling av benigna gynekologiska stoerningar | |
CA2467222A1 (en) | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy | |
HUP0100120A2 (en) | Pharmaceutical compositions comprising estrogen agonists/antagonists suitable for treating conditions responsive to estrogen | |
WO2008124922A1 (en) | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators | |
PA8523201A1 (es) | Nueva composicion farmaceutica | |
RU97104120A (ru) | Фармацевтические композиции, содержащие производные эстра-1,3,5(10)-триена | |
HK1046647B (zh) | 提高生育力的組合物 | |
BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
BRPI0409950A (pt) | métodos e composições usando hormÈnio de liberação de hormÈnio gonadotropina | |
AR050195A1 (es) | Un procedimiento para la preparacion de derivados 2-substituidos de estrona y estradiol. | |
PE20080995A1 (es) | 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
PE20001563A1 (es) | Antagonistas del receptor de vitronectina | |
GB0202635D0 (en) | Formulation containing novel anti-inflammatory androstane derivative | |
AR035064A1 (es) | 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos | |
UY28334A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. | |
PE20010579A1 (es) | Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos | |
EA200300491A1 (ru) | НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗО[b]ТИОФЕНА | |
RU2010100337A (ru) | ПРОИЗВОДНОЕ 17β-ЦИАНО-19-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, КОТОРЫЕ ВКЛЮЧАЮТ ПРОИЗВОДНОЕ | |
PE20010581A1 (es) | Mesoprogestinas (modulares de receptores de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (hrt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |